Listen on the go
CORRECT!
Next question
touchCARDIO touchCARDIO
Interventional Cardiology
Watch Time: 3 mins

PART TWO: Duk-Woo Park, ACC 2022: The efficacy and safety findings of the ADAPT-TAVR trial

Share this Video
Copy Link
Published Online: Apr 28th 2022

touchCARDIO spoke to Dr Duk-Woo Park (Asan Medical Center, Seoul, South Korea) to discuss his presentation at the American College of Cardiology Annual Meeting 2022, providing the results of the ADAPT-TAVR trial of edoxaban versus dual antiplatelet therapy for valve thrombosis and cerebral thromboembolism after transcatheter aortic-valve replacement. (To view Part One click here)

Questions

  1.       What were the aims and design of the ADAPT-TAVR study? 00:20-01:33
  2.       What were the efficacy and findings of the study? 01:33-02:34
  3.       What were the conclusions of the investigators regarding future clinical practice? 02:34-03:40

Speaker Disclosure: Duk-Woo Park discloses institutional research grants from Boston scientific, Abbott and Philips.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the American College of Cardiology Annual Meeting 2022

Related Videos In Interventional Cardiology
Devices, Interventional Cardiology
Developed by Touch
Gregg Stone, ACC 2023: Transcatheter edge-to-edge repair for functional mitral regurgitation in heart failure
Watch Time: 2 mins

Transcatheter edge-to-edge repair (TEER) is a minimally invasive procedure that can effectively treat functional mitral regurgitation in heart failure patients. Compared to traditional surgical approaches, TEER offers benefits such as reduced hospital stay, lower risk of bleeding and infection, and faster recovery time. Additionally, TEER has been found to improve symptoms and quality of life […]

Heart Failure, Interventional Cardiology
Developed by Touch
Gregg Stone, ACC 2023: COAPT trial results – Transcatheter edge-to-edge repair with MitraClip device for functional mitral regurgitation in heart failure
Watch Time: 5 mins

The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the […]

Interventional Cardiology
Developed by Touch
Hyo-Soo Kim, ACC 2023: Guidelines for the use of short-term dual antiplatelet therapy after coronary intervention
Watch Time: 2 mins

The guidelines for the use of short-term dual antiplatelet therapy (DAPT) after coronary intervention vary depending on the patient’s clinical situation and the type of intervention performed. In this touchCARDIO interview, we speak with Prof. Hyo-Soo Kim (Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea) to discuss the current guidelines for the […]

Trending In Interventional Cardiology:

Gregg Stone, ACC 2023: Transcatheter edge-to-edge repair for functional mitral regurgitation in heart failure
Devices, Interventional Cardiology
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72